Fibroblasts are major cellular components of the tumor microenvironment, regulating tumor cell behavior in part through secretion of extracellular matrix proteins, growth factors, and angiogenic factors. In previous studies, conditional deletion of the type II transforming growth factor-B (TGF-B) receptor in fibroblasts (Tgfbr2 FspKO ) was shown to promote mammary tumor metastasis in fibroblast-epithelial cell cotransplantation studies in mice, correlating with increased expression of hepatocyte growth factor (HGF). Here, we advance our findings to show that Tgfbr2 FspKO 
Introduction
Fibroblasts are a major cellular component of the stroma, influencing tumor cell behavior directly and indirectly through secretion of growth regulators and angiogenic factors, extracellular matrix proteins, and proteases (1, 2) . Studies have shown that heritable changes in the stroma, including mutations in the TP53 and PTEN genes, correlate with malignancy of breast cancers (3) . Furthermore, co-implantation of lymphoma, bladder, or mammary epithelial cells with carcinoma-associated, fetal, or irradiated fibroblasts result in enhanced tumor growth and invasion (4) (5) (6) (7) (8) (9) . These studies indicate that heritable changes in fibroblasts alter the signaling interactions with epithelial tumor cells to promote tumor progression.
A number of studies have shown an important role for transforming growth factor-h (TGF-h) signaling in regulating stromal-tumor interactions. TGF-h signaling exerts multiple effects in both stromal and epithelial cells, including inhibiting cell proliferation, promoting motility, and regulating differentiation. All of these cellular functions are achieved by binding of the TGF-h ligand to its cell surface type II receptor, which leads to recruitment and activation of its type I receptor and subsequent downstream signaling in the cytoplasm of multiple pathways, including SMAD, mitogen-activated protein kinase (MAPK), and Rho pathways (10, 11) . In cultured fibroblasts, TGF-h activates fibroblasts, inducing production of growth factors, angiogenic factors, extracellular matrix proteins, and proteases (12) (13) (14) . Studies from our laboratory using a conditional knockout of the TGF-h type II receptor in fibroblasts (Tgfbr2 FspKO ; ref. 15 ) have further revealed a significant role for TGF-h signaling in host-tumor interactions. Cre-mediated deletion of exon 2 of the Tgfbr2 gene flanked with loxP sites in fibroblasts was shown to abrogate TGF-h signaling in the stroma, resulting in the development of carcinoma of the forestomach and prostatic intraepithelial neoplasias in homozygous Tgfbr2 knockout mice (Tgfbr2 FspKO mice; ref. 16 ). Interestingly, although mammary development was severely inhibited in Tgfbr2
FspKO mice, mammary Tgfbr2 FspKO fibroblasts grafted with PyVmT or 4T1 mammary carcinoma cells in mice resulted in enhanced primary tumor growth and metastasis (17) compared with mice grafted with cre-negative control fibroblasts (homozygous floxed Tgfbr2 or Tgfbr2
Flox/Flox ), indicating a unique role for TGF-h signaling in the mammary stromal microenviroment. Tgfbr2 deficiency in fibroblasts was found to result in enhanced hepatocyte growth factor (HGF) secretion and correlate with enhanced phosphorylation of c-Met and Ron receptors in the mammary tumor epithelium (16, 17) , suggesting that interactions between TGF-h and HGF signaling were important in mediating stromal/epithelial interactions during mammary tumor progression.
Previous studies have established HGF as an important stromal-derived soluble factor in regulating normal and tumorigenic processes. Expressed primarily by fibroblasts, HGF has been shown to act on epithelial cells expressing cMet receptor tyrosine kinases to regulate a number of cellular processes, including cell proliferation, survival, migration, and branching, which are necessary for tissue development, including mammary development (11) . These cellular processes have been shown to be regulated by number of signaling pathways, including signal transducer and activator of transcription 3 (Stat3) and p42/44MAPK pathways (11, 18, 19) . Aberrant expression of HGF or c-Met has been correlated with the development of a number of cancers, including colorectal, renal, and breast cancers (20) , and overexpression or deletion of HGF and c-Met in animal studies confirm the oncogenicity of HGF signaling. Moreover, systemic blockade of c-Met signaling in orthotopic and xenograft mouse models using various inhibitors, including soluble receptors and small-molecule inhibitors (21) (22) (23) , have been shown to inhibit primary mammary tumor growth and metastatic spread. While the HGF/c-Met signaling pathways represent a promising therapeutic target, studies have shown that HGF may also regulate other receptor tyrosine kinases, including a c-Met -related receptor, Ron, to regulate tumorigenesis, whose functions in breast cancer still remain unclear (24, 25) . Understanding the multiple signaling pathways activated by HGF has an important implication in cancer therapeutics when predicting possible side effects and therapeutic outcome during patient treatment.
We had recently shown that specific inhibition of c-Met in a tumor xenograft model blocks metastatic spread caused by Tgfbr2
FspKO fibroblasts (26) . In the present studies, we advance our previous findings to show that TGF-h and HGF signaling interact to regulate fibroblast-tumor interactions at the molecular and cellular levels. Using multiple approaches, including pharmacologic blockade and small interfering RNA (siRNA) silencing to block HGF signaling, we show that Tgfbr2
FspKO fibroblasts enhance HGF/c-Met and HGF/Ron signaling pathways in mammary carcinoma cells to promote cell scattering and invasion. Furthermore, we show that HGF/c-Met and HGF/Ron signaling regulates these cellular process by mediating interactions between Stat3 and MAPK signaling. These studies characterize complex functional roles for HGF and TGF-h signaling in mediating tumorstromal interactions during mammary carcinoma cell scattering and invasion, with important implications in the tumor metastatic process.
Results

Tgfbr2
FspKO Fibroblasts Promote Mammary Carcinoma Cell Scattering and Invasion Associated with Enhanced HGF Signaling
The abilities of epithelial cells to undergo epithelial to mesenchymal transition, disassociate from the primary tumor, migrate, and invade through the basement membrane are important to the metastatic process. The effects of Tgfbr2 FspKO fibroblasts on cellular scattering and invasion of mammary carcinoma cells were determined through coculture of carcinoma cells and mammary fibroblasts, using immortalized Tgfbr2
Flox/Flox and Tgfbr2 FspKO fibroblasts, which were previously shown to behave in a similar and stable manner to primary mammary fibroblasts (17) . Conditioned medium from Tgfbr2
FspKO fibroblasts significantly increased 4T1 cell scattering compared with medium from control Tgfbr2 Flox/Flox fibroblasts or basal medium (Fig. 1) . Furthermore, Tgfbr2 In previous studies, primary tumors grafted with Tgfbr2
FspKO fibroblasts in nude mice showed increased levels of phosphorylated c-Met and Ron receptor proteins (17, 27) . To determine if this enhanced phosphorylation was specifically due to altered paracrine signaling interactions between the Tgfbr2
FspKO fibroblasts and mammary epithelial cells, 4T1 and PyVmT cells were treated with conditioned medium from Tgfbr2
Flox/flox control fibroblasts or Tgfbr2
FspKO fibroblasts and analyzed by Western blot. Tgfbr2
FspKO fibroblast conditioned medium significantly enhanced phosphorylation of the c-Met and Ron receptors and the downstream signaling proteins Stat3 and p42/ 44MAPK (Fig. 3A) . These effects correlated with increased levels of HGF transcripts in Tgfbr2
FspKO fibroblasts, according to Northern analysis (Fig. 3B) . Furthermore, neutralizing antibodies to HGF reduced phosphorylation of c-Met, Ron, Stat3, and p42/44MAPK proteins in 4T1 cells enhanced by Tgfbr2
FspKO fibroblast conditioned medium (Fig. 3C ). These results indicate that increased HGF expression from Tgfbr2-deficient fibroblasts enhance c-Met and Ron signaling in mammary carcinoma cells. FspKO fibroblasts in carcinoma cell scattering and invasion, HGF signaling was inhibited using multiple approaches. In previous studies, tumor-bearing mice treated with a vascular endothelial growth factor receptor (VEGFR)/ c-Met inhibitor, EXEL-7592, potently inhibited tumor growth and metastases and significantly decreased c-Met phosphorylation in primary mammary tumor tissues, compared with inhibition of VEGFR alone with EXEL-1075 (26) . These studies indicated a potential clinical significance for targeting the c-Met pathway in breast cancer with EXEL-7592, with a need to further determine the molecular and cellular mechanisms of this inhibitor. In the present studies, treatment of 4T1 cells with 250 nmol/L EXEL-7592 significantly reduced cell scattering induced by Tgfbr2
FspKO fibroblast conditioned medium, with increased numbers of rounded cell clusters Flox/Flox control fibroblasts or Tgfbr2
FspKO fibroblasts for 8 h. As a control, PyVmT and 4T1 tumor cells were seeded onto Matrigel-coated transwell filters in basal medium containing DMEM/F12/0.5% ABS in the absence of fibroblasts. Invaded tumor cells were visualized by fluorescence microscopy and micrographed at Â20 magnification; an overlay of invaded carcinoma cells and fibroblasts is shown. Statistical significance was determined by a two-tailed t test; *, P < 0.05, vs Tgfbr2
Flox/Flox fibroblasts. **, P < 0.001, vs Tgfbr2
Flox/Flox fibroblasts. Columns, mean; bars, SE.
( Fig. 4A ). EXEL-1075 treatment also reduced cell scattering induced by Tgfbr2
FspKO fibroblasts but was not found to be statistically significant. The inhibitory effect of EXEL-1075 was consistent with the low-level VEGFR2 expression detected in 4T1 tumor cells by Western analysis (data not shown). Neither EXEL-7592 nor EXEL-1075 significantly affected scattering of 4T1 cells treated with control Tgfbr2
Flox/Flox fibroblast conditioned medium, further indicating that Tgfbr2
FspKO fibroblasts specifically enhanced HGF signaling of 4T1 carcinoma cells.
As Tgfbr2 FspKO fibroblast conditioned medium enhanced the levels of phosphorylated c-Met and Ron receptor proteins, we determined the specific contribution of these receptors in cell scattering. Neutralizing antibodies to c-Met and Ron both FspKO fibroblasts significantly contribute 4T1 carcinoma cell scattering through both c-Met and Ron receptor activation.
We next determined the functional contribution of HGF signaling enhanced by Tgfbr2
FspKO fibroblasts in 4T1 carcinoma cell invasion. EXEL-7592 treatment inhibited carcinoma cell invasion more significantly than EXEL-1075. EXEL-1075 also inhibited 4T1 invasion enhanced by Tgfbr2
FspKO fibroblasts, consistent with low-level VEGFR2 expression in 4T1 cells detected by Western analysis (data not shown). Neither EXEL inhibitor significantly affected cellular invasion stimulated by control fibroblasts (Fig. 5A ). In addition, antibody neutralization of c-Met and Ron significantly inhibited 4T1 cell invasion enhanced by Tgfbr2-deficient fibroblasts, compared with control IgG treatment (Fig. 5B) . Similar effects of anti -c-Met and antiRon were also observed with PyVmT carcinoma cell invasion ( Supplementary Fig. S1C ). Consistently, c-Met -deficient and Ron-deficient 4T1 cells (4T1.MetÀ and 4T1.RonÀ) showed significantly decreased invasion through Matrigel matrix, compared with 4T1 parental or 4T1.GFPÀ cells (Fig. 5C ). These data indicate that Ron and c-Met receptor signaling in 4T1 enhanced by Tgfbr2-deficient fibroblasts is required for 4T1 carcinoma cell invasion.
As both c-Met and Ron receptors were shown to regulate cellular scattering and invasion enhanced by Tgfbr2 Experiments were done in replicates of four and repeated in triplicate. Quantitation of carcinoma cells was determined by measuring pixel density of CMTMR-labeled cells using Image J software (arbitrary units). Statistical significance was determined by a two-tailed t test: *, P < 0.001, vs Tgfbr2
FspKO fibroblasts/(À) inhibitor. **, P < 0.001, vs Tgfbr2
FspKO fibroblasts/(À) inhibitor. ***, P < 0.01, vs Tgfbr2 FspKO fibroblasts/IgG. ****, P < 0.01, vs Tgfbr2
FspKO fibroblasts/IgG. c, P < 0.05, vs 4T1.GFPÀ/ Tgfbr2
FspKO fibroblasts. b, P < 0.05, vs 4T1.GFPÀ/Tgfbr2 FspKO fibroblasts. Columns, mean; bars, SE.
exhibited reduced phosphorylation of Ron and Stat3 proteins (Fig. 7C) . These data suggest that c-Met and Ron receptors may function independently of each other, and that, in response to HGF, c-Met activates both Stat3 and p42/44MAPK signaling, whereas Ron receptors activate the Stat3 signaling pathway, with possible interactions at the Stat3 pathway.
We further analyzed the functional contribution of Stat3 and p44/42MAPK in HGF-induced scattering and invasion of 4T1 mammary carcinoma cells. Interestingly, the Stat3 peptide inhibitor (28) and the small-molecule Stat3 inhibitor, piceatannol (29) , significantly blocked HGF-induced phosphorylation of the mitogen-activated protein/extracellular signalregulated kinase kinase (MEK) and its downstream effector, p42/44MAPK, whereas the MEK inhibitors U0126 and PD98059 inhibited Stat3 phosphorylation in both 4T1 cells (Fig. 8A ) and PyVmT cells (Supplementary Fig. S2A ). Because U0126 and PD98059 inhibited phosphorylation of both MEK and p42/44MAPK, we determined if p42/44MAPK was specifically required for Stat3 signaling. 4T1 cells were transfected with siRNA duplexes to silence the expression of p42 and p44 MAPK isoforms, resulting in a 60% decrease in p42/44MAPK expression and a significant decrease in HGFinduced phosphorylation. 4T1 cells deficient in p42/44MAPK expression did not show significant changes in Stat3 phosphorylation (Fig. 8B) , suggesting that MEK, but not p42/ 44MAPK, was required for Stat3 signaling. Whereas treatment of 4T1 cells with PD98059 and Stat3 peptide inhibitors individually reduced HGF-induced scattering and invasion ( Fig. 8C and D) , simultaneous inhibition of Stat3 and p42/ 44MAPK signaling pathways did not result in either additive or synergistic blockade (Fig. 8C and D) . Similar results on cellular scattering were observed with MCF-7 and Madin-Darby canine kidney cells, whereas similar effects on cellular invasion were observed in PyVmT carcinoma cells ( Supplementary Fig. S2B and Fig. S2C ). These results suggest that Stat3 and MEK/ MAPK signaling pathways interact to mediate HGF-induced cell scattering and invasion of 4T1 mammary tumor cells.
Discussion
In previous studies using a tumor xenograft model, we showed an important role for TGF-h signaling in fibroblasts in regulating HGF/c-Met signaling between the stroma and mammary tumor epithelium during tumor progression (26). As c-Met has been shown to interact with additional receptor tyrosine kinases, including Ron (25), these studies suggest that enhancement of HGF signaling may have broader and more significant effects in altering fibroblast-carcinoma cell interactions than is currently known. In the present studies, we show that increased HGF expression by Tgfbr2
FspKO fibroblasts enhances mammary carcinoma cell scattering and invasion, through Ron and c-Met receptor signaling, which is in part regulated through cooperative interactions between the Stat3 and MAPK signaling pathways (Fig. 9) . Given that multiple cancer cell lines showed significant responses to Tgfbr2 FspKO fibroblasts, which were inhibited in the presence of c-Met and Ron inhibitors, these data indicate that the effects of Tgfbr2
FspKO fibroblasts are not restricted to one cell line but represent more global mechanisms of action.
Using multiple approaches, we analyzed the functional contribution of enhanced HGF expression in Tgfbr2-deficient fibroblasts on mammary carcinoma cell scattering and invasion. A partial reduction of c-Met and Ron phosphorylation with anti-HGF treatment suggests that additional factors secreted by Tgfbr2
FspKO fibroblasts may contribute to c-Met and Ron signaling in 4T1 mammary carcinoma cells, including TGF-a (17) . Signaling interactions between EGFR and c-Met receptors have been reported in human epidermoid carcinoma cells, PyVmT and 4T1 mammary carcinoma cells (30, 31) . The use of the small-molecular inhibitor EXEL-7592 most potently inhibited 4T1 cell scattering and invasion enhanced by Tgfbr2
FspKO fibroblasts. Interestingly, EXEL-1075 also slightly inhibited 4T1 cell scattering and potently inhibited invasion induced by Tgfbr2
FspKO fibroblasts. The low-level VEGFR2 expression in 4T1 cells is consistent with previous studies that have correlated expression of endothelial markers in metastatic breast cancer cells (32) . It would be of interest in the future to further investigate a potential role for VEGFR signaling in breast cancer cellular invasiveness. Specific inhibition of c-Met and Ron by receptor neutralizing antibodies and siRNA silencing also resulted in significant reductions in cell scattering and invasion induced by Tgfbr2
FspKO fibroblasts. As neutralizing antibodies to HGF inhibited phosphorylation of c-Met, Ron, p42/44MAPK, and Stat3 proteins, these data provide strong evidence that HGF derived from Tgfbr2-deficient fibroblasts enhance c-Met and Ron signaling in mammary carcinoma cells to promote cell scattering and invasion. In addition to c-Met, our data suggest that HGF may also signal through Ron receptor tyrosine kinases to regulate mammary carcinoma cell motility and invasion. Studies have associated the high-level expression of Ron with breast cancer malignancy in histologic and mouse tumor xenograft studies (30, 33) ; yet, little is currently known regarding the mechanisms of Ron signaling in fibroblast-mammary carcinoma interactions.
Our studies indicate that Tgfbr2
FspKO fibroblasts enhance epithelial cellular scattering and invasion partly through Ron signaling in multiple cell lines, including 4T1 PyVmT, MCF-7, and Madin-Darby canine kidney cell lines. Whereas other studies have shown that Ron is activated through direct ligand binding of macrophage-stimulating protein (25, 31) or through heterodimerization of Met and Ron (25), we observed that Ron phosphorylation was not significantly affected by c-Met inhibitors, suggesting that c-Met is not required for Ron phosphorylation. In recent studies, c-Met was not required for HGF binding of nucleolin and activation of downstream signaling in prostate cancer cells (34) , indicating that HGF has other binding partners. However, it is unlikely that HGF would bind Ron directly as studies have shown that HGF has no significant effect on Ron phosphorylation and does not interfere with Ron binding to macrophage-stimulating protein in ligand-binding studies (35, 36) . Evidence to support a possible indirect association between HGF and Ron comes from studies in which HGF binds to vitronectin and fibronectin in endothelial cells and promotes an integrin -c-Met downstream signaling (32) . In addition, HGF bind to heparin sulfate proteoglycans, in particular CD44, in colorectal cancer cells, resulting in CD44 interactions with c-Met to promote downstream signaling (37) . It is possible that similar mechanisms may exist involving HGF and Ron, in which HGF may bind to non -c-Met proteins to promote Ron signaling.
In our present study, a cooperative interaction was also observed between Stat3 and MAPK signaling pathways in mammary carcinoma cells. Cooperative roles between the MEK/MAPK and Stat3 signaling pathways have been reported in renal epithelial cells (38) and endothelial cells (39) in mediating cellular proliferation and survival, whereas antagonistic roles between Stat3 and MEK/MAPK signaling pathways have been reported in keratinocytes and liver progenitor cells (40, 41) . Such studies indicate that the interactions between Stat3 and MEK/MAPK signaling pathways are cell type specific, with important implications in targeting therapeutics. Studies have implicated both the MEK/MAPK and Stat3 signaling pathways in cytoskeletal reorganization through regulation of rac and rho GTPases, respectively (42, 43) . In addition, p42/44MAPK has been shown to regulate expression of extracellular matrix proteinases, including MMP9 (42, 44); Stat3 regulation of MMP1 and MMP2 has been implicated in tumor invasiveness (45) . Together, these studies suggest that Stat3 and MEK/MAPK signaling pathways function cooperatively in mammary carcinoma cells to regulate cell scattering and invasion, possibly directly through regulation of the actin cytoskeleton and indirectly through the expression of MMPs to alter the stromal microenvironment.
In summary, our studies show important functional roles of TGF-h and HGF signaling in mediating fibroblast-tumor interactions by demonstrating that HGF derived from Tgfbr2
FspKO fibroblasts regulates mammary tumor cell invasion, mediated through Ron and c-Met receptor signaling networks. Carcinoma cell invasiveness through the extracellular matrix is an important step in tumor metastasis, a process that remains a leading cause of death among cancer patients (46) . The challenges are due in part to limited understanding of the metastatic process, which result in difficulties in clinically detecting and treating micrometastases. It is therefore important to identify and understand the interplay of molecules involved in the metastatic process that would aid the design in more effective cancer therapeutics.
Materials and Methods
Chemicals
RNase-free buffer was purchased from Ambion. Prime-IT RmT kit was purchased from Stratagene. Growth Factor Reduced Matrigel was purchased from BD Biosciences. Rabbit IgG antibodies conjugated to horseradish peroxidase (anti-rabbit-hrp) and ECL Plus were purchased from Amersham/GE. Stat3 peptide inhibitor and piceatannol were purchased from Calbiochem. PD98059, U0126, and antibodies to phospho-c-Met (Y1234/1235), c-Met, phosphoStat3, Stat3, phospho-p42/44MAPK, p424/44MAPK were purchased from Cell Signaling Technologies. EXEL-7592 and EXEL-1075 were synthesized and purified in the Medicinal Chemistry Department at Exelixis, Inc. (47) . A 10 mmol/L stock solution was prepared in DMSO and diluted in optimal assay buffers or culture medium. Trizol reagent, Hybond Nylon Membrane, and CMTMR and CMFDA CellTracker dyes were purchased from Invitrogen/Molecular Probes. Recombinant mouse HGF and neutralizing antibodies to c-Met and Ron were purchased from R&D Systems. siRNAs to p42/44MAPK, scramble control siRNAs, siRNA transfection reagent, siRNA transfection medium, and antibodies to phospho-Ron (Y1238) and Ron were purchased from Santa Cruz Biotechnologies. Goat IgG, protease inhibitor cocktail, sodium orthovanadate, gelatin, and fibronectin were purchased from Sigma. Ten percent neutral formalin buffer was purchased from vWR.
Cell Lines
Mammary fibroblasts from control Tgfbr2 Flox/Flox and Tgfbr2
FspKO mice were spontaneously immortalized and previously characterized (17) . Fibroblast cell lines were cultured on plastic in DMEM/F12 5% adult bovine serum (ABS). PyVmT mammary carcinoma cells were isolated from MMTV-PyVmT transgenic mice as previously described (17) and cultured on plastic in DMEM containing 10% fetal bovine serum with antibiotics. 4T1 mammary carcinoma cells [generously provided by the laboratory of Fred Miller (University of Michigan, Ann Arbor, MI)] and the 4T1 sublines 4T1.GFPÀ, 4T1.3MetÀ, and 4T1.1RonÀ were cultured on plastic in DMEM containing 10% fetal bovine serum with antibiotics. Generation of c-Met -deficient (4T1.3MET) and siRNA specificity control (4T1.GFPÀ) were generated and characterized as previously described (26) . Generation of a Ron-deficient 4T1 cell line was generated through stable expression of pGabe retroviral vector carrying siRNAs to Ron according to the methods previously described (26) .
Generation of Fibroblast-Conditioned Medium
Tgfbr2 Flox/Flox and Tgfbr2 FspKO fibroblasts were plated in 10-cm dishes in DMEM/F12/5% ABS for 24 h. The complete medium was aspirated and cells were then incubated in 4 mL of DMEM/F12 containing 0.1% ABS for 24 h. The conditioned medium was then removed, filtered through 0.4-Am filtration unit, and used for the experiments indicated.
Northern Blot analysis
Tgfbr2 Flox/Flox and Tgfbr2 Fspko fibroblasts were plated in 10-cm dishes (300,000 per plate) in complete medium for 24 h. The medium was aspirated and the cells were lysed in 1 mL Trizol reagent (Invitrogen), vortexed with 500 AL phenol/choloroform, and centrifuged for 5 min at 12,000 rpm. The aqueous layer was extracted and the RNA was precipitated with 500 AL isopropanol at À20jC overnight. Samples were pelleted at 12,000 rpm for 10 min, washed with 75% ethanol, and resuspended in RNase-free buffer (RNase Secure). Ten micrograms of total RNA were resolved in 1% agarose gel containing 2.2 mol/L formaldehyde, 1Â 3-[N-morpholino]proponesulfonic acid, DEPC, and ethidium bromide. The RNA was transferred to a Hybond nylon membrane and probed with a HGF cDNA fragment labeled with [ 32 P]dCTP using a Prime-IT RmT kit according to the manufacturer's protocol. Membranes were washed with 2Â SSC at room temperature, followed by two stringent washes (1Â SSC at 65jC for 10 min and 0.5Â SSC at 65jC for 10 min), before exposure to film.
siRNA Silencing of p42/44MAPK p42/44MAPK expression was silenced by transient transfection of siRNAs in 4T1 cells, according to the manufacturer's protocol. Briefly, 4T1 cells (200,000) were plated in a 6-well dish and incubated in serum-free medium with a complex of 500 ng of p42/44MAPK siRNA or control scramble siRNA and 16 AL siRNA/transfection reagent for 8 h. The transfected cells were incubated with siRNA/ transfection reagent complexes in complete medium for an additional 24 h. The medium containing siRNA/transfection reagent complexes was aspirated and replaced with fresh complete medium.
Western Blot Analyses of Cultured 4T1 Tumor Cells
4T1 parental and sublines were cultured to 80% confluency, starved in serum-free medium for 24 h, and then treated with 60 ng/mL HGF in the presence or absence of inhibitors in serum-free medium for 30 min.
The tumor cells were lysed in radioimmunoprecipitation assay buffer containing 10 mmol/L Tris-HCl (pH 8.0), 0.1 mmol/L EDTA, 0.1% sodium deoxycholate, 0.1% SDS, 140 mmol/L NaCl supplemented with protease inhibitor cocktail containing aprotinin, leupeptin, bestatain, and pepstatin A and 10 mmol/L sodium orthovanadate. Fifty micrograms of protein were fractionated on 8% to 12% SDS PAGE gels. The proteins were transferred to nitrocellulose membranes and then probed with antibodies (1:1,000) to the phosphorylated and unphosphorylated forms of c-Met, Ron, p42/44MAPK, or Stat3. Specific immunoreaction was detected using anti-rabbit-hrp and ECL Plus chemiluminescence.
Scatter Assay
Scatter assays were done as described (48) . Briefly, 500 4T1 cells per well were plated in a 24-well plate and cultured to clusters of 20 to 30 cells. After 24 h of starvation in serum-free medium, cells were stimulated in 60 ng/mL HGF in the presence or absence of inhibitors for 24 h, fixed in neutral formalin buffer, and stained in Mayer's hematoxylin for 30 min at room temperature. Cells were visualized by phase contrast microscopy and micrographed at Â20 magnification with 10 fields per sample. Quantitation of cell scattering was determined by calculating the number of cell scattered per cell cluster. Each experimental group was plated in triplicate wells, with a minimum count of 10 samples per well. Experiments were done in triplicate. The data are represented as mean values with error bars reflected as SE.
Invasion Assay
Tumor cells were labeled with 1.5 Amol/L CMTMR (red) flourochrome whereas mammary fibroblasts were labeled with 1.5 Amol/L CMFDA (green) fluorochrome in serum-free medium for 45 min at 37jC. The medium containing the dye was aspirated and cells were allowed to recover for 24 h. For HGF stimulation experiments, tumor cells were serum starved for 24 h and then seeded on top of the transwell (75,000) in the presence or absence of 60 ng/mL HGF and inhibitors and incubated at 37jC for 8 h. For fibroblasttumor coculture experiments, 100,000 fibroblasts were seeded on the underside of the transwell 8-Am-pore filter (BD Biosciences) coated with Growth Factor Reduced Matrigel. CMTMR-labeled tumor cells (75,000) were then seeded in DMEM/F12 0.5% ABS on top of the transwell filter in the presence or absence of fibroblasts and inhibitors and incubated for 8 h. The cells were fixed in 10% neutral formalin buffer for 10 min. Tumor cells on the topside of the filter were removed by cotton swab. The transwell filter was mounted on glass slides in aqua-based mounting medium. Invaded tumor cells were visualized by fluorescence microscopy and micrographed at Â20 magnification, three fields per sample. Experiments were done in replicates of four and repeated in triplicate. Quantitation of tumor cells was determined by measuring pixel density of redlabeled cells using Image J (NIH) software (arbitrary units). The data are represented as mean values with error bars reflected as SE.
Statistical Analysis
Analyses of study results focused on estimating the association between the study groups, e.g., Tgfbr2
FspKO fibroblasts versus Tgfbr2
Flox/Flox fibroblasts, and study end points. The tests of hypotheses concerning the single measurement of outcome data, e.g., number of invaded cells, were carried out using either through the two-tailed Student's t test or ANOVA. All tests of significance were two sided and differences were considered statistically significant when P < 0.05.
